Innophos (NASDAQ:IPHS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
A number of other brokerages also recently commented on IPHS. KeyCorp restated a “hold” rating on shares of Innophos in a research note on Wednesday, November 1st. Zacks Investment Research upgraded Innophos from a “hold” rating to a “strong-buy” rating and set a $54.00 target price on the stock in a research note on Tuesday, August 8th.
Innophos (IPHS) opened at $45.49 on Tuesday. The company has a current ratio of 2.86, a quick ratio of 1.49 and a debt-to-equity ratio of 0.83. Innophos has a twelve month low of $41.66 and a twelve month high of $58.22. The firm has a market capitalization of $902.63, a price-to-earnings ratio of 18.79 and a beta of 0.86.
Innophos (NASDAQ:IPHS) last issued its earnings results on Tuesday, October 31st. The specialty chemicals company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.06. Innophos had a return on equity of 13.90% and a net margin of 6.19%. The firm had revenue of $184.00 million for the quarter, compared to the consensus estimate of $179.33 million. During the same quarter in the previous year, the company posted $0.69 earnings per share. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. analysts expect that Innophos will post 2.5 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Personal Capital Advisors Corp grew its stake in Innophos by 2.7% in the third quarter. Personal Capital Advisors Corp now owns 60,902 shares of the specialty chemicals company’s stock valued at $2,996,000 after purchasing an additional 1,603 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Innophos by 38.5% during the 2nd quarter. Prudential Financial Inc. now owns 172,021 shares of the specialty chemicals company’s stock worth $7,541,000 after acquiring an additional 47,830 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Innophos by 68.8% during the 2nd quarter. American Century Companies Inc. now owns 612,435 shares of the specialty chemicals company’s stock worth $26,849,000 after acquiring an additional 249,585 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in shares of Innophos during the 2nd quarter worth about $2,556,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Innophos by 0.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 973,461 shares of the specialty chemicals company’s stock worth $42,676,000 after acquiring an additional 3,717 shares in the last quarter. Hedge funds and other institutional investors own 94.46% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thelincolnianonline.com/2017/12/07/bidaskclub-downgrades-innophos-iphs-to-sell.html.
Innophos Company Profile
Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.
Receive News & Ratings for Innophos Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.